Dyne Therapeutics委任Barry E. Greene為獨立董事 授予期權強化管治

8-K
 
 
 
 0001818794false00018187942026-06-222026-06-22

  

  
UNITED STATES 
SECURITIES AND EXCHANGE COMMISSION 
WASHINGTON, D.C. 20549 
 
FORM 8-K
 
CURRENT REPORT 
Pursuant to Section 13 or 15(d) 
of the Securities Exchange Act of 1934 
Date of report (Date of earliest event reported): June 22, 2026
 
Dyne Therapeutics, Inc.
(Exact Name of Registrant as Specified in Charter) 
 
 

 
 
 
 
 
 

 
 Delaware

 001-39509

 36-4883909

 

 
 (State or Other Jurisdiction
of Incorporation)

 (Commission
File Number)

 (IRS Employer
Identification No.)

 

 
  

  

  

 

 
 1560 Trapelo Road
Waltham, Massachusetts

  

 02451

 

 
 (Address of Principal Executive Offices)

  

 (Zip Code)

 

  
Registrant’s telephone number, including area code: (781) 786-8230
Not applicable 
(Former Name or Former Address, if Changed Since Last Report) 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): 
 

 
 
 
 
 

 
 ☐

 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

 

 

 
 
 
 
 

 
 ☐

 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

 

 

 
 
 
 
 

 
 ☐

 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

 

 

 
 
 
 
 

 
 ☐

 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 

 

 Securities registered pursuant to Section 12(b) of the Act: 
 

 
 
 
 
 
 
 
 

 
 Title of each class

 

 Trading symbol(s)

 

 Name of each exchange on which registered

 

 
 Common stock, $0.0001 par value per share

 

 DYN

 

 Nasdaq Global Select Market

 

  
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). 
Emerging growth company ☐ 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 
 
 

  

 
  

 Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. 
On June 22, 2026, the Board of Directors (the “Board”) of Dyne Therapeutics, Inc. (the “Company”), upon recommendation from the Nominating and Corporate Governance Committee of the Board, elected Barry E. Greene as a Class I director to serve on the Board until the Company’s 2027 Annual Meeting of Stockholders and until his successor has been duly elected and qualified or until his earlier death, resignation or removal. Mr. Greene has not been appointed to serve on any committees of the Board. The Board has determined that Mr. Greene is an “independent” director under the Nasdaq Stock Market rules. 
Mr. Greene shall be entitled to receive compensation under the Company’s non-employee director compensation program. In accordance with this program, upon his election to the Board, Mr. Greene received, under the Company’s 2020 Stock Incentive Plan, an option to purchase 57,463 shares of the Company’s common stock at an exercise price equal to $20.87 per share, the closing price of the Company’s common stock on the date of grant, which option will vest and become exercisable in equal monthly installments over the next three years, subject to his continued service. In the event of a change in control of the Company, the vesting schedule of the option will accelerate in full. In addition, Mr. Greene will receive annual cash compensation of $45,000 as a member of the Board, annual equity grants in accordance with the non-employee director compensation program and reimbursement for reasonable travel and out-of-pocket expenses incurred in connection with attending Board meetings. 
There are no arrangements or understandings between Mr. Greene and any other persons pursuant to which he was elected as a director. Mr. Greene does not have any family relationships with any of the Company’s directors or executive officers. There are no transactions and no proposed transactions between Mr. Greene and the Company that would be required to be disclosed pursuant to Item 404(a) of Regulation S-K. 
Mr. Greene will enter into the Company’s standard form of indemnification agreement. The form of the indemnification agreement was filed as Exhibit 10.10 to the Company’s Registration Statement on Form S-1 filed with the U.S. Securities and Exchange Commission on August 25, 2020.
 

  

 
  

 SIGNATURES 
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. 
 

 
 
 
 
 
 
 
 
 
 

 
  

  

  

  

  

  

  

 

 
  

 

 DYNE THERAPEUTICS, INC.

 

 
  

  

  

 

 
 Date: June 22, 2026

 

 By:

 

 /s/ John G. Cox

 

 
  

 

  

 

 Name:

 

 John G. Cox

 

 
  

 

  

 

 Title:

 

 President and Chief Executive Officer